Zai Lab to Announce Third Quarter 2021 Financial Results

Rhea-AI Summary

Zai Lab Limited (NASDAQ: ZLAB) announced that it will release its financial results for Q3 2021 on November 9, 2021, after U.S. markets close. A conference call and webcast is scheduled for November 10, 2021, at 8:00 a.m. ET. This biopharmaceutical company focuses on innovative therapies in oncology, autoimmune disorders, and infectious diseases, with a commitment to addressing unmet medical needs. Investors can access the conference call through their website after registering in advance.

Positive

• Company to report Q3 2021 results on November 9, 2021.
• Live conference call scheduled for November 10, 2021, may enhance investor communication.

Negative

• None.

SHANGHAI, SAN FRANCISCO and CAMBRIDGE, Mass., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that it will report financial results and corporate updates for the third quarter ended September 30, 2021 after the closing of the U.S. equity markets on November 9, 2021. The Company will host a live conference call and webcast on November 10, 2021, at 8:00 a.m. ET.

Conference Call and Webcast Information

Listeners may access the live webcast by visiting the Company's website at http://ir.zailaboratory.com. Participants must register in advance of the conference call. Details are as follows:

Registration Link:	http://apac.directeventreg.com/registration/event/9666772
Conference ID:	9666772

All participants must use the link provided above to complete the online registration process in advance of the conference call. Upon registering, each participant will receive a dial-in number, Direct Event passcode, and a unique access PIN, which can be used to join the conference call.

A replay will be available shortly after the call and can be accessed by visiting the Company's website at http://ir.zailaboratory.com.

About Zai Lab

Zai Lab (NASDAQ: ZLAB; HKEX: 9688) is a patient-focused, innovative, commercial-stage, global biopharmaceutical company focused on developing and commercializing therapies that address medical conditions with unmet needs in oncology, autoimmune disorders and infectious disease. To that end, our experienced team has secured partnerships with leading global biopharmaceutical companies in order to generate a broad pipeline of innovative marketed products and product candidates. We have also built an in-house team with strong product discovery and translational research capabilities and are establishing a pipeline of proprietary product candidates with global rights. Our vision is to become a leading global biopharmaceutical company, discovering, developing, manufacturing and commercializing our portfolio in order to impact human health worldwide.

For additional information about the company, please visit www.zailaboratory.com or follow us at www.twitter.com/ZaiLab_Global.

For more information, please contact:

ZAI LAB CONTACTS:

Investor Relations: Ron Aldridge / Lina Zhang
+1 (781) 434-8465 / +86 136 8257 6943
ronald.aldridge@zailaboratory.com / lina.zhang@zailaboratory.com

Media: Danielle Halstrom / Xiaoyu Chen
+1 (215) 280-3898 / +86 185 0015 5011
danielle.halstrom@zailaboratory.com / xiaoyu.chen@zailaboratory.com

Zai Lab Limited

FAQ

When will Zai Lab report its Q3 2021 financial results?

Zai Lab will report its Q3 2021 financial results on November 9, 2021, after the U.S. market closes.

What is the date and time of Zai Lab's conference call?

The conference call will take place on November 10, 2021, at 8:00 a.m. ET.

How can I access the Zai Lab conference call?

You can access the conference call by registering through Zai Lab's website at http://ir.zailaboratory.com.

What is Zai Lab's focus in the biopharmaceutical industry?

Zai Lab focuses on developing therapies for oncology, autoimmune disorders, and infectious diseases.